News briefing: AbbVie and Roche's Venclexta scores another FDA OK; ImmunoGen nabs China deal with $40M cash
AbbVie and Roche’s Venclexta has gotten a new FDA thumbs up.
The pair announced Monday that regulators have approved the drug in combination with azacitidine or low-dose cytarabine for newly-diagnosed acute myeloid leukemia in adults who are 75 or older or those who can’t undergo intensive chemotherapy. This follows the drug’s accelerated approval in 2018 and positive data from two Phase III confirmatory trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.